Journal
PHARMACEUTICALS
Volume 14, Issue 5, Pages -Publisher
MDPI
DOI: 10.3390/ph14050417
Keywords
hepatitis B; hepatitis B virus; HBV; antiviral agents; HBV inhibitors; cccDNA; HBV life cycle; HBV treatment; nucleoside analogues; antiviral therapy
Categories
Funding
- Special Account for Research Grants
- National and Kapodistrian University of Athens
Ask authors/readers for more resources
Hepatitis B virus infection has a significant global impact, with limitations in current antiviral drugs. Recent research on the viral replication cycle has led to the development of novel therapeutic approaches, providing hope for achieving a functional cure of the infection in the future.
Hepatitis B virus infection affects over 250 million chronic carriers, causing more than 800,000 deaths annually, although a safe and effective vaccine is available. Currently used antiviral agents, pegylated interferon and nucleos(t)ide analogues, have major drawbacks and fail to completely eradicate the virus from infected cells. Thus, achieving a functional cure of the infection remains a real challenge. Recent findings concerning the viral replication cycle have led to development of novel therapeutic approaches including viral entry inhibitors, epigenetic control of cccDNA, immune modulators, RNA interference techniques, ribonuclease H inhibitors, and capsid assembly modulators. Promising preclinical results have been obtained, and the leading molecules under development have entered clinical evaluation. This review summarizes the key steps of the HBV life cycle, examines the currently approved anti-HBV drugs, and analyzes novel HBV treatment regimens.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available